Acute otitis media (AOM), defined by NICE as middle ear effusion associated with acute onset of symptoms and signs of middle ear inflammation, occurs frequently in children as a com plication of URTI when inflammation of the upper airway extends from the nasopharynx to the ear through the Eustachian tube. 4, 5 Children are predisposed to AOM due to the shorter length of their Eustachian tubes, which are more horizontal and more prone to obstruction by enlarged adenoids. 6 Approximately 10% of children will have had an episode of AOM by three months of age, and by three years of age, approximately 50-85% will have experienced at least one episode. 7 
Diagnosis and assessment
Differentiating acute bacterial URTIs from viral can be challeng ing since 20-40% of children diagnosed with acute sinusitis based on clinical criteria likely have a viral URTI. 8 NICE recom mends that all children presenting to primary care with a history suggestive of an URTI or AOM should be offered a full clinical assessment. 9 Where possible, clinicians should attempt to determine a specific diagnosis; see Table 1 , taken from the British Thoracic Society's guidance for the assessment and management of cough in children. 3 Children under three months of age present ing with fever should be referred to hospital for assessment
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Despite the majority of infections being viral and self-limiting, children are still frequently prescribed antibiotics for upper respiratory tract infections (URTIs) and acute otitis media. This article discusses how to assess whether an antibiotic is appropriate and when referral to secondary care may be necessary.
by a paediatrician as per the NICE feverish illness in children guidance (see Table 2 ).
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For children presenting with sore throat, NICE guidance recommends that the Centor clinical predictor be used to aid the diagnosis or exclusion of bacterial tonsillitis but should not be relied upon. 11 The Centor clinical predictor tool was originally developed for use in adults and consists of four crite ria: presence of fever, tender anterior cervical lymph node, ton sillar exudate and absence of cough. 12 The presence of three or four of these clinical signs indicates a 40-60% chance of group A Streptococcus infection and hence the patient may benefit from antibiotic treatment. 11 In clinical practice, the Centor criteria can be an ineffective predictor of bacterial ton sillitis in children and is rarely used. In children, the presence of fever and tonsillar exudate alone is a strong indicator of bacterial tonsillitis. Although NICE does not advocate routine use of throat swabs, they can be useful to exclude a diagnosis of bacterial tonsillitis in children and reduce inappropriate prescribing of antibiotics.
Public Health England (PHE)'s 2016 guidance on managing common infections in primary care now recommends the use of the Fever PAIN score. 13 The Fever PAIN score was derived from a cohort study including 1760 adults and children aged three years and over, which concluded that use of the score resulted in more rapid symptom resolution and reduced prescribing of antibiotics. The score consists of five items: fever during previ ous 24 hours, purulence, attend surgery rapidly (less than three days), very inflamed tonsils and no cough/coryza.
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• Fever PAIN score of 0-1: only 1318% have Streptococcus, close to background carriage, therefore a no antibiotic strategy is appropriate with discussion • Fever PAIN score of 2-3: 3440% have Streptococcus, there fore a backup/delayed antibiotic is appropriate with discussion • Fever PAIN score of >4: 62-65% have Streptococcus, there fore consider immediate antibiotic if symptoms are severe, or a short 48hour delayed antibiotic prescribing strategy may also be appropriate after agreement with the patient/carers with safety netting advice.
Patients unable to tolerate oral medications or those with com plications such as acute epiglottitis should be referred to hos pital.
A diagnosis of AOM is usually made clinically where symp toms may include pain (ear tugging in young children), fever, irritability, and problems feeding and sleeping. Otoscopic appearances typical of AOM include bulging tympanic mem brane, with loss of normal landmarks, red or yellow in colour, and poor mobility. 15 NICE guidance recommends admission for paediatric assessment of all children under three months of age with a temperature of 38°C or more and children with sus pected acute complications of AOM such as meningitis, mas toiditis or facial nerve paralysis. 4 
Treatment options
There is currently no national clinical guideline in the UK relat ing to antibiotic prescribing in primary care for URTIs that are likely to be selflimiting. The main emphasis of management is symptom relief of fever, nasal congestion and coughing. 
Antipyretics and analgesics
Although the safety profiles of antipyretics and analgesics such as paracetamol and ibuprofen are good and the sideeffects minimal, NICE recommends that these agents should only be used in children to reduce fever that is associated with pain or distress, and stress the importance of avoiding unnecessary use of these agents in children with selflimiting viral illness.
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Parents and carers should be advised that paracetamol or ibuprofen alone may be used if the child appears to be distressed or in pain; use of paracetamol and ibuprofen in combination is not recommended, since the clinical benefit is considered to be too small. Parents and carers may be advised to switch to the alternative medication if the child's distress is not alleviated. 16 Clinicians should ensure parents and carers have a clear understanding of the dosage and frequency of administration of these products and that counselling on the appropriate meas uring device (eg spoon or oral syringe) is provided.
Over-the-counter cough and cold preparations
Following initial concerns raised in the USA, in 2009 the Medicines and Healthcare products Regulatory Agency (MHRA) conducted a review of the risks and benefits associated with the use of overthecounter (OTC) cough and cold medications in chil dren under 12 years of age. The review found no robust evidence to support the use of the medications listed below in children under six years of age. Given that these medications can cause sideeffects such as allergic reactions, effects on sleep and hal lucinations, the balance of risk versus benefit was not shown to be favourable and the advice is that these medications should no longer be used in children under six years of age:
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• Nasal decongestants (pseudoephedrine, ephedrine, phenyl ephrine, oxymetazoline and xylometazoline)
• Antihistamines (diphenhydramine, chlorphenamine, bromphe niramine, promethazine, triprolidine and doxylamine)
• Antitussives (dextromethorphan and pholcodine)
• Expectorants (guaifenesin and ipecacuanha).
Products for children aged 6 to 12 years of age containing these ingredients are still available for purchase from phar macies, with clearer advice on the packaging. Following this, in 2010 the MHRA also reviewed the use of OTC cough and cold medications containing codeine for use in children. These medications are no longer recommended for use in children and young people under the age of 18 years.
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For younger children, saline nose drops can loosen dried nasal secretions and relieve congestion. Parents and carers can also be advised to try tickling the child's nose with a cotton bud to cause sneezing to clear the nose. Although advice to use steam inhalation is still occasionally given in primary care, there is no evidence of effectiveness and reports of mild thermal injury are well documented. This treatment option should therefore be discouraged. 19 Parents and carers should be advised to ensure their child rests and remains adequately hydrated.
Antibiotic prescribing
It is estimated that 90% of URTIs are selflimiting and caused by viruses, hence antibiotic use remains contentious. 20 Despite little evidence of benefit, antibiotic prescribing for children with uncomplicated URTIs remains widespread in the UK, with approximately 33% of childhood consultations for URTI resulting in an antibiotic prescription. 21, 22 Unnecessary antibiotic prescribing contributes to the increasing burden of antimicrobial resistance, which is a major public health concern. Parents' or carers' concerns and expec tations should be determined and addressed, and clinicians should consider the risks versus benefits of antibiotic prescrib ing. The NICE guidance on the prescribing of antibiotics for res piratory tract infections concludes that there is good evidence that antibiotics are of limited efficacy in treating the majority of URTIs and AOM in adults and children. 9 Delayed prescription of antibiotics is recommended in international guidance; NICE and PHE currently recommend using a strategy of either no antibiotic prescribing or delayed antibiotic prescribing for the management of uncomplicated sore throat and other URTIs in children over three months of age once the child has had a thorough clinical examination of the tonsils. 9, 21 Unnecessary antibiotic prescribing within primary care is partly due to the inability to exclude bacterial infection. Rapid pointofcare (POC) tests that can be performed within the dura tion of a GP consultation could assist clinicians with the deci sion to prescribe antibiotics in the future. Rapid antigen tests that detect the presence of group A streptococcal antigen on a throat swab are currently available but they have poor sensitivity and hence have little impact on prescribing decisions.
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Where antibiotic treatment is deemed necessary for sus pected bacterial tonsillitis, NICE and PHE recommend treatment with a 10day course of phenoxymethylpenicillin. For children with a true penicillin hypersensitivity, treatment with a fiveday course of clarithromycin or erythromycin is recommended. Macrolides have a broader spectrum of activity than phenoxy methylpenicillin and thus are more likely to drive the emergence of bacterial resistance.
11,13,23 Phenoxymethylpenicillin remains the antibiotic of choice for suspected bacterial tonsillitis, based on a combination of its proven efficacy, narrow spectrum, safety and cost effectiveness.
11,13 Phenoxymethylpenicillin is availa ble in a childfriendly suspension formulation (125mg/5ml or 250mg/5ml) and tablet formulation (250mg) for those children who are able to swallow. Dosage frequency is four times a day, ideally on an empty stomach. Phenoxymethylpenicillin is not particularly palatable, making compliance in children difficult. Amoxicillin and other broadspectrum antibiotics are not rec ommended for empiric treatment of sore throats in children; however, if adherence to phenoxymethylpenicillin is likely to be an issue, these alternatives may be considered, providing there is no possibility of glandular fever.
11 Antibiotic dosing recom mendations are outlined in Table 3 .
Where antibiotic treatment is deemed necessary for sus pected AOM, NICE and PHE recommend treatment with a fiveday course of amoxicillin. For children with a true penicillin hyper sensitivity, treatment is with a fiveday course of clarithromycin or erythromycin. 4, 13, 23 Amoxicillin is effective against the likely bacterial pathogens involved in AOM, including Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, and Moraxella catarrhalis. 4 Macrolides have less activity against H. influenzae than amoxicillin. 4 Azithromycin may be associated with greater development of resistance than the other mac rolides, owing to its greater halflife, and is therefore not recom mended despite the possibility of increased adherence with its oncedaily regimen. 21 Amoxicillin is available as a childfriendly suspension formulation (125mg/5ml or 250mg/5ml) and cap sule formulation (250mg or 500mg) for those children who are able to swallow. Dosage frequency is three times daily (with or without food), which allows for doses to be administered at home for children attending nursery or school. Amoxicillin is generally well tolerated by children, with diarrhoea, nausea and vomiting being the most common sideeffects along with skin rash. The suspension is also fairly palatable. Antibiotic dosing recommendations are outlined in Table 3 .
Although clarithromycin suspension is twice the price of erythromycin suspension, it is still often considered the pre ferred macrolide for treatment in children with confirmed pen icillin allergy owing mainly to its reduced sideeffect profile and reduced dosage frequency. Like amoxicillin, clarithromy cin is also available as a childfriendly suspension formulation (125mg/5ml or 250mg/5ml) and tablet formulation (250mg or 500mg) for those children who are able to swallow. Dosage frequency is twice daily, making clarithromycin a more practical option than erythromycin, which has a dosage frequency of four times daily. Clinicians should be aware of potential drug inter actions and take care when prescribing macrolides.
Most antibiotic suspensions will require storage in the refrigerator once reconstituted, and parents and carers should be advised to shake the bottle before giving each dose and to space doses as evenly as possible throughout the child's wak ing day. Clinicians should ensure parents and carers are given advice on the natural history of the illness and they should be reminded of the importance of ensuring all antibiotic doses are given and the course is completed. Antibiotic liquids can be administered using either the measuring spoon provided or an oral syringe. For babies, parents and carers should be advised to administer doses down the side of the cheek and avoid mixing doses with feeds, as in the event that the whole feed is not taken, this may result in only a proportion of the dose being administered. For children attending nursery/school, a twice daily or threetimes daily antibiotic regimen may be pref erable to avoid needing to administer a dose during the nurs ery/school period. Administration of medicines in nurseries/ schools can be complex and if medications are required to be administered, they will need to be in their original containers and clearly labelled with the child's name and administration instructions.
Summary
URTIs are common in childhood but are usually viral and selflimiting. The mainstay of management is symptom relief with simple analgesics. There is no evidence of benefit for the use of OTC cough and cold preparations and these should not be recommended. Despite the predominantly viral cause, chil dren are frequently prescribed antibiotics for the treatment of URTIs and AOM. Inappropriate prescribing of antibiotics contrib utes to the increasing prevalence of antimicrobial resistance, which is recognised as a major threat to public health. NICE and PHE recommend three antibiotic prescribing strategies for children presenting to primary care with symptoms of an uncomplicated URTI or AOM: no prescribing, delayed prescribing and immediate prescribing. The prescribing strategy should be decided based on the child's clinical presentation and should take into account any risk factors. Where the decision is made not to prescribe antibiotics, parents and carers should be offered reassurance that antibiotics are not required as they are unlikely to make a difference and may potentially cause sideeffects. They should be advised to return if symptoms worsen or become prolonged.
